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ABSTRACT 
Background:  Lactobacilli  are  the  well  known  friendly  bacteria  for  their  probiotic  activities  against  pathogens.  The 
inhibitory activity of different strains of lactobacilli either obtained as commercial products or isolated from human feces 
was investigated against the clinical isolates of Pseudomonas aeruginosa. The isolates were selected as the most resistant 
strains when challenged with anti-pseudomonal antibiotics already in clinical practice.
Materials and Methods: Both the plate spot test as well as the agar cup method were used for screening of Lactobacillus 
strains against Pseudomonas aeruginosa. 
Results: A Lactobacillus acidophilus strain isolated from feces of an Iranian child showed a strong anti-pseudomonal activity 
(90 percent after 72h incubation) against the multi-drug resistant clinical isolates while a Lactobacillus reuteri strain isolated 
from a commercial oral product resulted in relatively weak response and a Lactobacillus acidophilus strain isolated from a 
commercial vaginal product did not show any inhibitory activity. In a kinetic study the lactobacillus sensitive Pseudomonas 
aeruginosa showed a significant bacteriostatic activity in vitro in the presence of lactobacillus supernatants. 
Conclusion: Some lactobacilli exhibit significant inhibitory activity against the multidrug resistant clinical isolates of 
Pseudomonas aeruginosa. 
Key words: Lactobacillus species, Anti-pseudomonal activity, Pseudomonas aeruginosa
INTRODUCTION
Multi-drug resistant bacteria are the cause of numer-
ous clinical problems throughout the world. Increas-
ed resistance among pathogens causing nosocomial 
and community acquired infections is known to be 
related to the widespread utilization of antibiotics (1). 
Infectious diseases caused by resistant microorganisms 
are accountable for increased health costs as well as 
high morbidity and mortality, especial-ly in developing 
countries. Pseudomonas aeruginosa is an opportunis-
tic gram negative bacterium which is a major cause of 
nosocomial infections, usually occurring in the context 
of serious underlying diseases and accounting for nearly 
10%  of  all  hospital-acquired  infections  of  surgical 
sites, the respiratory tract and the urinary tract (2, 3). 
It is also prevalently related to otitis media and nasal 
infections and represents a leading cause of morbidity 
due to burn wound infection (4, 5). P. aeruginosa 
has inherent resistance to most available antibiotics, 
including  aminoglycosides,  anti-pseudomonal 
penicillins,  newer  cephalosporins,  imipenem  and 
flouroquinolones as treatment options for systemic 
infections (6-8). Recent reports have documented the 
role of exogenous Lactobacilli in the prevention and 
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and amikacin (purchased from Padtan Teb Company, 
Tehran,  Iran)  was  investigated  using  Kirby-Bauer 
disk diffusion method and by comparing their growth 
inhibition zones to those reported by CLSI (15-18). 
The diameters of inhibition zones were measured and 
compared with the zones suggested by CLSI, using 
susceptible  strains  as  control.  From  these  isolates, 
three  strains  were  selected  for  supernatant  mixed 
culture test. 
Antimicrobial  assay.  The  inhibitory  activity  of 
different Lactobacillus strains was screened against 
multiple  drug  resistant  Pseudomonas  aeruginosa 
using conventional agar spot test (19). Furthermore, 
the effect of supernatants of screened Lactobacillus 
strains on growth of the Pseudomonas aeruginosa 
was confirmed by the agar cup method (20). Briefly, 
24-hr-old  positive  Lactobacillus  cultures  in  MRS 
broth were centrifuged at 5500 g for 10 min at 4oC. 
The supernatants were discarded, and 0.1 ml of the 
precipitant was used for the study of antibacterial 
activity.  The  antibacterial  activity  of  metabolites 
produced  by  screened  samples  of  Lactobacillus 
strains was further investigated by supernatant mixed 
culture technique. Potent strains were incubated in 5 
ml of MRS broth (pH 6.4) and Pseudomonas spp. 
were incubated in 5 ml of Muller-Hinton broth (pH 
7.2),  both  for  24  hrs  in  conventional  conditions. 
1  ml  por-tions  of  supernatants  of  the  centrifuged 
Lactobacillus cultures were mixed with 1 ml of the 
test strains cultures (4 × 105 CFU/ml) in Muller-
Hinton broth. The optical densities of culture media 
treatment of some infections. Lactobacillus strains are 
commensal in the human body. Oral administration of 
Lactobacillus strains has been found to be useful in 
various  bacterial  infections  (9-11).  Its  beneficial 
effect may be associated to its ability to inhibit the 
growth of pathogens, apparently by the secretion 
of  antibacterial  substances  including  lactic  acid, 
hydrogen peroxide and etc. (12). We undertook this 
in vitro study to evaluate the effects of different 
Lactobacilli-either obtained as commercial products 
or isolated from an Iranian villager child feces and 
their metabolites on multiple drug resistant clinical 
isolates of Pseudomonas aeruginosa. 
MATERIALS AND METHODS
Bacterial stains and growth conditions. A number 
of 55 clinical isolates of P. aeruginosa were collected 
from Imam and Shariati University Hospitals, Tehran, 
Iran. Identification of the isolates was conducted using 
conventional  isolation  methods  (13).  Lactobacillus 
acidophilus  JFSH  was  originally  isolated  from  a 
villager child’s stool. Lactobacillus acidophilus and 
Lactobacillus reuteri strains were originally isolated 
from commercial products (14). Lactobacillus strains 
were grown in Lactobacillus MRS Broth at 37ºC for 
24 h.
Susceptibility testing. Susceptibility of the strains 
to  12  antibiotics  including  cephradin,  ampicillin, 
ceftriaxon, chloramphenicol, cefotaxime, ceftazidime, 
tobramycin,  piperacillin,  imipenem,  gentamicin 
Antibiotics
Pseudomonas aeruginosa 
Resistant n (%) Susceptible n (%)
Gentamicin (10 µg) 27 (49.0) 15 (27.2)
Ciprofloxacin (5 µg) 14 (25.4) 32 (58.1)
Amilcacin (30 µg) 24 (43.6) 22 (40.0)
Tobramycin (10 µg) 10 (33.3) 7 (23.3)
Ceftazidime (30 µg) 37 (67.2) 11 (20.0)
Cefotaxime (30 µg) 30 (54.5) 9 (16.3)
Cephradin (30 µg) 55 (100) 0 (0)
Chloramphenicol (30 µg) 9 (16.3) 6 (10.9)
Piperacillin (100 mcg) 42 (76.3) 13 (23.7)
Imipenem (10 mcg) 41 (74.5) 14 (25.5)
Ceftriaxon (30 mcg) 46 (83.6) 9 (16.4)
Ampicillin (30 mcg) 55 (100) 0 (0)
Table 1. Resistance percentage of P. aeruginosa to various antimicrobial agents (Total population = 55).23 ANTI-Pseudomonas ACTIvITy LACTOBACILLUS
were  measured  at  0,  6,  12,  18  and  24  hrs  after 
incubation at 580 nm. Also the CFU were counted 
by the spread-plate technique.
Effect  of  lactic  acid,  hydrogen  peroxide,  and 
buffer on Pseudomonas strains. The effects of lactic 
acid  (pH  2.0)  and  hydrogen  peroxide  (pH  6.5)  at 
the concentrations of 3 % v/v on Pseudomonas spp. 
growth were tested by the agar cup method.
RESULTS
The  resistant  pattern  of  55  P.  aeruginosa  to 
antimicrobial agents is shown in Table 1. Moreover, 
all tested strains showed resistance against cephradin 
and ampicillin. Low susceptibility of tested strains 
against  other  potent  antimicrobial  agents  is  also 
shown  (Table  1).  Five  potent  lactobacillus  strains 
were selected among 200 samples by agar spot test 
and  agar  cup  method  (Fig.  1). These  strains  were 
further  identified  by  conventional  techniques  for 
characterization  of  Lactobacillus  species  (listed  in 
Table 2). The antibacterial activity of the supernatants     
of these autochthonus Lactobacilli and also commer-
cially  Lactobacillus  acidophilus  and  Lactobacillus 
reuteri  were  tested  against  10  highly  resistant 
strains of P. aeruginosa (Table 2). A Lactobacillus 
acidophilus strain isolated from the feces of an Iranian 
villager child showed a strong and unchanged activity 
for 72 hrs against the multiple drug resistant clinical 
isolates while Lactobacillus reuteri and Lactobacillus 
gasseri  from  an  oral  product  resulted  in  relatively 
Bacteria
The percentage of inhibitory activity 
48 (h) 72 (h)
Lactobacillus plantarium 40 80
Lactobacillus acidophilus 40 90
Lactobacillus casei 10 90
Lactobacillus fermentum 60 20
Lactobacillus reuteri 20 70
Lactobacillus gasseri 30 70
Lactobacillus acidophilus (commercial) 0 0
H2O2 3% 0 100
Lactic acid 3% 0 100
Table 2. Inhibitory activity of the supernatants of some Lactobacillus cultures against multiple resistant P. aeruginosa at 48 
and 72 hrs.
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Figure 1. Inhibition effect of Lactobacillus plantarium culture supernatant by the agar 
well diffusion assay.  
Ρ
Fig. 1. Inhibition effect of Lactobacillus plantarium culture 
supernatant by the agar well diffusion assay. 
Fig.  2.  Antibacterial  activity  of  Lactobacillus  casei, 
Lactobacillus acidophilus and Lactobacillus reuteri against 
Pseudomonas  aeruginosa.  The  surviving  CFU/ml  was 
quantitated after 0 h, 3 h, 6 h, 9 h, 12 h, 15 h, and 18 h.
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Fig.ure 1.: Antibacterial activity of L Lactobacillus casei, Lactobacillus acidophilus and 
Lactobacillus  reuteri  against  Pseudomonas  aeruginosa.  The  surviving  CFU/ml  was 
quantitated after 0h, 3h, 6h, 9h, 12h, 15h, and 18h. 
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weak response and a Lactobacillus acidophilus strain 
isolated from a commercial vaginal product did not 
show  any  inhibitory  activities.  Examination  of  the 
killing kinetics (Fig. 2) revealed that Lactobacillus 
casei,  Lactobacillus  acidophilus  and  Lactobacillus 
reuteri  had  an  obvious  improvement  in  killing 
P.  aeruginosa.  A  sensitive  P.  aeruginosa  to  all 
Lactobacillus strains was selected as the test strain 
for time killed curve study.
DISCUSSION
The inhibitory activity of lactic acid bacteria against 
some resistant clinical isolates of P. aeruginosa has 
been reported. None of the antimicrobial agents was 
effective  against  all  the  multi-drug  tested  strains 
demonstrating the current problem in the treatment of 
multi-drug resistant nosocomial infections. In previous 
studies   P.  aeruginosa isolates showed intermediate 
or  fully  resistance  to  antimicrobial  agents  (21-26). 
Unfortunately, P. aeruginosa strains showed complete 
resistance against cephradin and ampicillin. Further-
more, its susceptibility to other potent antimicrobial 
agents,  including  ceftriaxon,  chloramphenicol, 
cefotaxime,  ceftazidime,  tobramycin,  piperaciliin, 
imipenem, gentamicin and amikacin ,which are used 
more in hospital infections, was also tested.  Lactic acid 
bacteria are dispersed in nature such as in dairy, fish, 
vegetable and grains. They are also found in normal 
vaginal  flora  and  protect  the  vagina  from  urinary 
tract  infection.  In  fact,  many  strains  of  the  genus 
lactobacillus are capable of colonizing specific parts 
of the body, e.g. the oral cavity and the gastrointestinal 
and uro-genital tract, where they play an important 
role in the competitive exclusion of pathogen (27, 
28). Antimicrobial activity of Lactobacillus strains 
against  bacterial  pathogens  emerges  to  be  multi-
factorial and to include the production of hydrogen 
peroxide,  lactic  acid,  bacteriocin-like  molecules 
and unknown heat-stable, non-lactic acid molecules 
(29). Other mechanisms proposed for their activity 
are competition for nutrients (30, 31), and adhesion 
inhibition  of  pathogens  to  surface  and  simulation 
of the immune system (32). The results show that 
the  metabolites  of  lactoba-cillus  acidophilus  and 
also two other strains could suppress the growth of 
P.  aeruginosa,  but  no  decrease  in  viable  count  of  P. 
aeruginosa was seen in the supernatants of different 
lactobacilli in 18 hrs. Research has demonstrated that 
this inhibitory activity of lactobacilli can be different 
in liquid medium compared to solid medium because 
of  better  diffusion  of  the  substance  secreted  by 
lactobacillus (33).
In some studies, the probiotic activities of Lactoba-
cillus administered vaginally have been evaluated in 
woman with urinary tract infection (34-37). In one of 
these studies, five females suffering from recurrent 
urinary  tract  infections  were  treated  twice  weekly 
with  intra-vaginal  and  perineal  implantation  of 
Lactobacillus casei GR-1, and has been found that that 
L. casei GR-1 inhibited the growth of the coliforms 
bacteria (36). It has been showed that lactobacillus 
vaginal suppositories are safe and may be effective 
in reducing the recurrence of urinary tract infections 
(UTI)  following  three  days  antimicrobial  therapy 
with norfloxacin or trimethoprim/sulfamethoxazole 
(TMP/SMX) in forty-one adult women with acute 
lower UTI (37).
Lactobacilli  are  able  to  inhibit  the  growth  of  P. 
aeruginosa by different mechanisms. These friendly 
bacteria could act as bio-therapeutic microorganisms 
and  might  be  good  candidates  to  overcome  the 
growing challenge of nosocomial infections due to 
multi-drug resistant strains of P. aeruginosa. 
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